The Four-Component LNP Architecture That Defines the Field

Lipid nanoparticles are self-assembled colloidal delivery vehicles, typically 50–200 nm in diameter, built from four canonical components that together determine efficacy, safety, and organ tropism. The ionizable lipid is the primary functional driver: bearing a pKa typically between 6.0 and 7.0, it remains uncharged at physiological pH but becomes protonated in the acidic endosomal environment after cellular uptake, triggering membrane disruption and releasing nucleic acid cargo into the cytoplasm. The remaining three components — a phospholipid helper (such as DSPC or DOPE) for membrane structure, cholesterol or a cholesterol derivative for membrane stability and fusion, and a PEG-lipid for particle size control and immune evasion — complete the architecture that underpins every major approved LNP product.

Innovation within the ionizable lipid component has been the most active sub-domain in the retrieved dataset. Filings from Moderna TX, Acuitas Therapeutics, and Alnylam Pharmaceuticals all describe novel ionizable lipid structures incorporating branched tail groups and tertiary amine head groups specifically designed to enhance endosomal escape activity. Alnylam’s WO-2022261392-A1, for example, describes ionizable lipid compounds with branched tail groups and tertiary amine head groups for robust siRNA silencing in hepatocytes following systemic administration. Acuitas Therapeutics’ US-2023355790-A1 claims improved in vivo efficacy and reduced cytotoxicity, with high encapsulation efficiency and controlled release in target tissues including liver, lung, and spleen.

Cholesterol derivatives have also attracted attention as a means of improving membrane fusion with endosomal membranes. Sanofi’s EP-4151205-A1 demonstrates that specific oxidized and esterified cholesterol derivatives improve cargo release into the cytoplasm, with the modified LNPs showing superior in vivo transfection efficiency in liver and extrahepatic tissues compared to conventional cholesterol-containing formulations. This signals that even the structural lipid component — long considered the most inert element of the four-component system — is now an active site of differentiation. According to WIPO, nucleic acid delivery technologies have been among the fastest-growing patent filing categories in the pharmaceutical sector over the past five years.

From Platform Validation to Target Expansion: The 2022–2024 Innovation Arc

The 30-patent dataset reveals a clear three-phase innovation arc: foundational lipid chemistry in late 2022, rapid application diversification through 2023, and manufacturing infrastructure investment in early 2024. All publications cluster within the 2022–2024 window, reflecting the post-COVID-19 vaccine acceleration of the LNP field.

The earliest filings in this dataset (Q4 2022) focus on foundational ionizable lipid design and biodegradable lipid chemistry. Alnylam Pharmaceuticals’ WO-2022261392-A1, Moderna TX’s US-2022370624-A1 on biodegradable ionizable lipids, and GSK’s WO-2022261369-A1 on self-amplifying RNA (saRNA) vaccine adjuvant systems all represent continuations or improvements on pre-pandemic platform work. The biodegradable lipid approach — incorporating ester linkages in hydrophobic tails that are cleaved by intracellular esterases — is particularly significant: it enables more rapid lipid clearance and reduced hepatotoxicity while delivering mRNA with comparable or superior efficacy to non-biodegradable formulations.

“The mid-2023 cluster — at least 16 of 30 retrieved patents — shows diversification into extrahepatic targeting, CNS delivery, and cancer immunotherapy, marking the transition from platform validation to target expansion.”

The mid-2023 cluster is the most densely populated in this dataset. It encompasses the University of Texas System’s SORT LNP technology (WO-2023081526-A2), Spark Therapeutics’ intrathecal CNS delivery system (EP-4218739-A1), and BioNTech SE’s personalised mRNA cancer vaccine platform (WO-2023230295-A1). The most recent filings from Q1–Q2 2024 signal movement toward manufacturing infrastructure and cancer immunotherapy at scale, exemplified by Precision NanoSystems’ microfluidic manufacturing disclosure (US-2024115517-A1) and Moderna TX’s cancer immunotherapy LNP composition (US-2024100434-A1). Research published by Nature has highlighted LNP-mediated mRNA delivery as one of the most consequential platform technologies in modern medicine.

Application Domains: From Liver Dominance to Whole-Body Reach

Hepatic delivery has historically been the default destination for systemically administered LNPs, driven by the liver’s fenestrated vasculature and high expression of ApoE receptors that facilitate LNP uptake. Within the retrieved dataset, liver-targeted applications — including siRNA gene silencing for hypercholesterolaemia and transthyretin amyloidosis, and CRISPR-based cardiovascular risk reduction — remain well represented. However, the dataset reveals a decisive shift in innovation energy toward extrahepatic targets.

Liver: The Established Base

Liver-targeted LNPs benefit from well-established biology. Alnylam Pharmaceuticals’ siRNA LNPs (US-2023149536-A1) incorporate GalNAc or apolipoprotein E (ApoE)-mediated targeting mechanisms to enhance hepatic uptake via the LDL receptor pathway, with applications including hypercholesterolaemia, transthyretin amyloidosis, and other liver-expressed genetic diseases. Daiichi Sankyo’s GalNAc-modified LNPs (JP-2023106320-A) target hepatocytes via the asialoglycoprotein receptor (ASGPR) for treating hepatitis B and non-alcoholic steatohepatitis. Verve Therapeutics has extended the hepatic LNP paradigm into cardiovascular gene editing, delivering base editor proteins and guide RNA to efficiently edit the PCSK9 gene in the liver for durable LDL cholesterol reduction — a single-dose, permanent cardiovascular risk reduction approach.

Extrahepatic Targets: Lung, Spleen, CNS, and Tumour

The SORT (Selective Organ Targeting) technology from the University of Texas System (WO-2023081526-A2) represents the most systematic approach to extrahepatic delivery in the dataset. SORT LNPs incorporate supplemental lipid components that re-route biodistribution through modulation of protein corona composition, enabling delivery to the lung, spleen, and bone marrow. Fudan University’s CN-115969966-A demonstrates similar principles using a library of novel ionizable lipids with varied head group architectures to preferentially deliver to lung epithelial cells and splenic immune cells compared to conventional MC3-based LNPs.

For pulmonary delivery, ReCode Therapeutics (WO-2023196634-A1) describes LNPs formulated for inhalation that direct nucleic acid cargo specifically to lung epithelial cells, with applications in cystic fibrosis, COPD, and acute respiratory distress syndrome. CNS delivery via intrathecal administration is represented by Spark Therapeutics’ EP-4218739-A1, which demonstrates expression of therapeutic proteins in spinal motor neurons and brain tissue for conditions including spinal muscular atrophy, ALS, and Huntington’s disease — with reduced neuroinflammatory response compared to viral vectors. According to the NIH, non-viral delivery of nucleic acids to the CNS represents one of the most significant unmet needs in gene therapy.

Cancer-targeted LNPs incorporate active targeting via antibody conjugation and passive accumulation via the enhanced permeability and retention (EPR) effect. Nitto Denko’s US-2023172955-A1 describes LNPs conjugated with anti-PD-L1 antibody fragments and folate receptor ligands for selective delivery of siRNA and mRNA to solid tumours, while Genentech’s US-2023201326-A1 uses site-specific conjugation chemistry to attach targeting moieties to T cells, B cells, hepatocytes, and tumour cells without disrupting LNP structure or cargo encapsulation.

Manufacturing Scale-Up and Storage Stability as Competitive Differentiators

Manufacturing reproducibility and cold-chain independence are increasingly recognised as strategic bottlenecks that determine which LNP platforms can reach global markets. The dataset contains several filings that treat these as primary innovations rather than secondary considerations, signalling their growing competitive importance.

Precision NanoSystems’ US-2024115517-A1 describes microfluidic systems using chaotic advection mixing and precise control of flow rate ratios to produce LNPs with uniform size distribution and high encapsulation efficiency. The system is explicitly designed to be scalable from bench to clinical manufacturing and supports GMP-compliant production of mRNA-LNP formulations, achieving batch-to-batch reproducibility suitable for pharmaceutical manufacturing. Pfizer’s EP-4122497-A1 similarly claims long-term storage stability at 2–8°C and high mRNA encapsulation efficiency, with manufacturing methods using scalable microfluidic processes. The European Medicines Agency has published guidance on the characterisation and quality standards expected for LNP-based medicines, further raising the bar for manufacturing reproducibility.

PEG-lipid engineering also intersects with both stability and pharmacokinetics. Merck Sharp & Dohme’s US-2023338306-A1 describes PEG-lipid conjugates with tunable dissociation kinetics — providing a stealth effect during systemic circulation while allowing PEG shedding in target tissues for enhanced cellular uptake. This addresses the longstanding tension between circulation stability (requiring a PEG corona) and cellular uptake efficiency (which PEG inhibits), and represents a meaningful advance over conventional PEG-lipid formulations in terms of pharmacokinetic profile and prolonged circulation half-life.

Emerging Frontiers: In Vivo Cell Engineering and Personalised Cancer Vaccines

Two application domains in the dataset represent the furthest extension of LNP technology from its origins: in vivo CAR-T cell engineering and personalised neoantigen cancer vaccines. Both leverage the mRNA delivery capability of LNPs but require substantially more sophisticated targeting and formulation strategies than systemic liver delivery.

Umoja Biopharma’s WO-2023220708-A1 describes LNP compositions engineered for in vivo reprogramming of T cells to express chimeric antigen receptors (CARs). The LNPs incorporate anti-CD3 or anti-CD8 targeting ligands to selectively transfect T lymphocytes in vivo, enabling CAR-T cell therapy without ex vivo manufacturing. The approach uses mRNA delivery to generate transient CAR expression, enabling repeated dosing — a significant departure from the permanent gene modification of conventional CAR-T manufacturing. Applications include treatment of hematologic malignancies and solid tumours.

“In vivo CAR-T cell engineering via LNPs — incorporating anti-CD3 or anti-CD8 targeting ligands to selectively transfect T lymphocytes — enables CAR-T therapy without ex vivo manufacturing, representing a fundamental reimagining of cell therapy economics.”

Personalised mRNA cancer vaccines represent the other frontier application. BioNTech SE’s WO-2023230295-A1 describes personalised mRNA cancer vaccines comprising neoantigen-encoding mRNA sequences specific to an individual patient’s tumour mutation profile, delivered via LNPs that enhance mRNA stability, facilitate lymph node targeting, and promote dendritic cell activation. Clinical applications include treatment of melanoma, lung cancer, and other solid tumours. Moderna TX’s US-2024100434-A1 extends this to broader cancer immunotherapy, with LNPs formulated for intratumoral or intravenous administration to activate CD8+ T cell responses against tumour neoantigens, optionally co-encapsulating immune adjuvants for synergistic immunostimulation.

GSK’s WO-2022261369-A1 on self-amplifying RNA (saRNA) vaccine adjuvant systems — which combine saRNA or mRNA encoding viral antigens with toll-like receptor (TLR) agonist adjuvants in LNPs — points toward a broader infectious disease vaccine pipeline encompassing influenza, RSV, HIV, and emerging pathogens. The LNP adjuvant system is designed to enhance antigen presentation and prolong immune activation, generating robust humoral and cellular immune responses. These developments align with the strategic priorities outlined by the World Health Organization for next-generation vaccine platforms capable of rapid response to emerging infectious threats.

The CRISPR delivery frontier is represented by Shandong University’s CN-117257972-A, which describes LNP compositions for delivering CRISPR-Cas9 components — including Cas9 mRNA and guide RNA (sgRNA) simultaneously — to target tissues including liver and lung, applicable for treating sickle cell disease, beta-thalassaemia, and hypercholesterolaemia. The simultaneous co-delivery of two distinct nucleic acid cargoes within a single LNP formulation represents a meaningful technical advance over sequential or separate delivery approaches. PatSnap’s own innovation intelligence resources provide further context on gene editing delivery platform trends, and the PatSnap R&D solution enables teams to monitor CRISPR-LNP patent activity in real time.